CTNM — Contineum Therapeutics Income Statement
0.000.00%
- $452.99m
- $335.08m
- $50.00m
- 28
- 30
- 68
- 37
Annual income statement for Contineum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 0 | 0 | 50 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Total Operating Expenses | 28.6 | 22.7 | 33.9 |
Operating Profit | -28.6 | -22.7 | 16.1 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -29 | -24.3 | 23.2 |
Provision for Income Taxes | |||
Net Income After Taxes | -29 | -24.3 | 22.7 |
Net Income Before Extraordinary Items | |||
Net Income | -29 | -24.3 | 22.7 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -29 | -24.3 | 22.7 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -1.15 | -0.965 | 0.904 |